FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281654076> ?p ?o ?g. }

• W4281654076 abstract "Rett syndrome (RTT) is a devastating neurodevelopmental disorder without effective treatments. Attempts at developing targetted therapies have been relatively unsuccessful, at least in part, because the genotypical and phenotypical variability of the disorder. Therefore, identification of biomarkers of response and patients’ stratification are high priorities. Administration of Insulin-like Growth Factor 1 (IGF-1) and related compounds leads to significant reversal of RTT-like symptoms in preclinical mouse models. However, improvements in corresponding clinical trials have not been consistent. A 20-weeks phase I open label trial of mecasermin (recombinant human IGF-1) in children with RTT demonstrated significant improvements in breathing phenotypes. However, a subsequent randomised controlled phase II trial did not show significant improvements in primary outcomes although two secondary clinical endpoints showed positive changes. To identify molecular biomarkers of response and surrogate endpoints, we used RNA sequencing to measure differential gene expression in whole blood samples of participants in the abovementioned phase I mecasermin trial. When all participants ( n = 9) were analysed, gene expression was unchanged during the study (baseline vs. end of treatment, T0–T3). However, when participants were subclassified in terms of breathing phenotype improvement, specifically by their plethysmography-based apnoea index, individuals with moderate-severe apnoea and breathing improvement (Responder group) displayed significantly different transcript profiles compared to the other participants in the study (Mecasermin Study Reference group, MSR). Many of the differentially expressed genes are involved in the regulation of cell cycle processes and immune responses, as well as in IGF-1 signalling and breathing regulation. While the Responder group showed limited gene expression changes in response to mecasermin, the MSR group displayed marked differences in the expression of genes associated with inflammatory processes (e.g., neutrophil activation, complement activation) throughout the trial. Our analyses revealed gene expression profiles associated with severe breathing phenotype and its improvement after mecasermin administration in RTT, and suggest that inflammatory/immune pathways and IGF-1 signalling contribute to treatment response. Overall, these data support the notion that transcript profiles have potential as biomarkers of response to IGF-1 and related compounds." @default.
• W4281654076 created "2022-06-13" @default.
• W4281654076 creator A5015614800 @default.
• W4281654076 creator A5024300858 @default.
• W4281654076 creator A5029784901 @default.
• W4281654076 creator A5046553667 @default.
• W4281654076 creator A5070865606 @default.
• W4281654076 creator A5077764504 @default.
• W4281654076 creator A5079691093 @default.
• W4281654076 creator A5083294545 @default.
• W4281654076 date "2022-05-31" @default.
• W4281654076 modified "2023-10-18" @default.
• W4281654076 title "Molecular Signatures of Response to Mecasermin in Children With Rett Syndrome" @default.
• W4281654076 cites W1488115555 @default.
• W4281654076 cites W1559742681 @default.
• W4281654076 cites W1979302263 @default.
• W4281654076 cites W1989780964 @default.
• W4281654076 cites W2012807815 @default.
• W4281654076 cites W2015748323 @default.
• W4281654076 cites W2029960467 @default.
• W4281654076 cites W2030912492 @default.
• W4281654076 cites W2048273592 @default.
• W4281654076 cites W2054775186 @default.
• W4281654076 cites W2057198053 @default.
• W4281654076 cites W2079159166 @default.
• W4281654076 cites W2083407341 @default.
• W4281654076 cites W2087457070 @default.
• W4281654076 cites W2092597282 @default.
• W4281654076 cites W2095900642 @default.
• W4281654076 cites W2099517884 @default.
• W4281654076 cites W2102148167 @default.
• W4281654076 cites W2103017472 @default.
• W4281654076 cites W2104054545 @default.
• W4281654076 cites W2105926864 @default.
• W4281654076 cites W2109555365 @default.
• W4281654076 cites W2112481119 @default.
• W4281654076 cites W2114104545 @default.
• W4281654076 cites W2120502497 @default.
• W4281654076 cites W2120860183 @default.
• W4281654076 cites W2127311839 @default.
• W4281654076 cites W2148093798 @default.
• W4281654076 cites W2149119305 @default.
• W4281654076 cites W2154057943 @default.
• W4281654076 cites W2164502083 @default.
• W4281654076 cites W2168058242 @default.
• W4281654076 cites W2168126378 @default.
• W4281654076 cites W2172958821 @default.
• W4281654076 cites W2260832166 @default.
• W4281654076 cites W2272398100 @default.
• W4281654076 cites W2333386541 @default.
• W4281654076 cites W2414910334 @default.
• W4281654076 cites W2466314544 @default.
• W4281654076 cites W2494449917 @default.
• W4281654076 cites W2516577108 @default.
• W4281654076 cites W2519972465 @default.
• W4281654076 cites W2526053553 @default.
• W4281654076 cites W2546757431 @default.
• W4281654076 cites W2559812869 @default.
• W4281654076 cites W2596220192 @default.
• W4281654076 cites W2598132736 @default.
• W4281654076 cites W2734032654 @default.
• W4281654076 cites W2786122698 @default.
• W4281654076 cites W2789492951 @default.
• W4281654076 cites W2790333198 @default.
• W4281654076 cites W2801770351 @default.
• W4281654076 cites W2841079612 @default.
• W4281654076 cites W2922881551 @default.
• W4281654076 cites W2942653846 @default.
• W4281654076 cites W2989333414 @default.
• W4281654076 cites W2995513120 @default.
• W4281654076 cites W3007969610 @default.
• W4281654076 cites W3037010733 @default.
• W4281654076 cites W3046255814 @default.
• W4281654076 cites W3111846485 @default.
• W4281654076 cites W3112600195 @default.
• W4281654076 cites W3128141932 @default.
• W4281654076 cites W3195572553 @default.
• W4281654076 cites W4241872665 @default.
• W4281654076 cites W4255146584 @default.
• W4281654076 doi "https://doi.org/10.3389/fnins.2022.868008" @default.
• W4281654076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35712450" @default.
• W4281654076 hasPublicationYear "2022" @default.
• W4281654076 type Work @default.
• W4281654076 citedByCount "2" @default.
• W4281654076 countsByYear W42816540762023 @default.
• W4281654076 crossrefType "journal-article" @default.
• W4281654076 hasAuthorship W4281654076A5015614800 @default.
• W4281654076 hasAuthorship W4281654076A5024300858 @default.
• W4281654076 hasAuthorship W4281654076A5029784901 @default.
• W4281654076 hasAuthorship W4281654076A5046553667 @default.
• W4281654076 hasAuthorship W4281654076A5070865606 @default.
• W4281654076 hasAuthorship W4281654076A5077764504 @default.
• W4281654076 hasAuthorship W4281654076A5079691093 @default.
• W4281654076 hasAuthorship W4281654076A5083294545 @default.
• W4281654076 hasBestOaLocation W42816540761 @default.
• W4281654076 hasConcept C104317684 @default.
• W4281654076 hasConcept C126322002 @default.
• W4281654076 hasConcept C143998085 @default.
• W4281654076 hasConcept C203092338 @default.
• W4281654076 hasConcept C2777543196 @default.

• next